---
layout: default
title: "Case PPEGC-2025-0002"
---

# Case PPEGC-2025-0002

**Submitting Institute:** North American institution (NAM-023), USA  
**Publication Date:** February 16, 2025  
**DOI:** 10.ppegc/2025-0002

---

## Clinical Information

| | |
|---|---|
| **Cancer Type** | Metastatic melanoma |
| **Stage** | Stage IV (M1c) |
| **Patient Age Range** | 55-60 years |
| **Sex** | Male |
| **Treatment** | Vemurafenib 960mg BID |
| **Prior Lines** | First-line therapy |

---

## Genomic Profile

| Gene | Variant (HGVS) | VAF | Type |
|---|---|---|---|
| BRAF | NM_004333.6:c.1799T>A (p.Val600Glu) | 65% | Somatic |
| PTEN | NM_000314.8:c.388C>T (p.Arg130Ter) | 58% | Somatic |

**Sequencing Method:** Whole exome sequencing (WES)

---

## Exceptional Phenotype

**Type:** Unexpected resistance (Primary resistance)

**Description:**  
Patient with BRAF V600E-mutant metastatic melanoma showing progressive disease (PD) on vemurafenib despite confirmed V600E mutation. Molecular profiling revealed concurrent PTEN loss-of-function mutation (nonsense mutation R130*), rarely detected at baseline.

**Timeline:**
- Baseline: Multiple liver, lung, and subcutaneous metastases
- Week 4: Increased size of liver lesions (+15%)
- Week 8: New brain metastases, progression in all target lesions (+35%)
- Treatment discontinued, switched to ipilimumab/nivolumab

**Exceptional Features:**
1. Primary resistance to BRAF inhibitor despite canonical V600E mutation
2. PTEN loss detected at baseline (unusual in treatment-naive melanoma)
3. Rapid progression (8 weeks vs typical first progression at 6-9 months)

**Post-Treatment Findings:**
- Subsequent immunotherapy (ipi/nivo): Partial response achieved
- Brain metastases controlled with stereotactic radiosurgery
- Patient alive at 18 months follow-up

**Hypothesis:**  
Concurrent PTEN loss may confer primary resistance to BRAF inhibition via constitutive PI3K/AKT pathway activation, bypassing BRAF dependency.

---

## Key Insights

- First reported case of PTEN nonsense mutation detected at baseline in BRAF V600E melanoma
- Supports pre-treatment molecular profiling beyond BRAF testing
- Suggests PTEN loss as potential biomarker for primary BRAF inhibitor resistance
- Patient tumor DNA available for collaborative research

---

## Interested in this case?

üìß **Request contact with the submitting clinician**  
[Contact PPEGC](mailto:curation@ppegc.org?subject=Contact%20Request%20-%20PPEGC-2025-0002)

üìù **Report a similar case**  
[Submit your case](https://redcap.link/ppegc-submit)

ü§ù **Propose a research collaboration**  
[Collaboration inquiry](mailto:research@ppegc.org?subject=Collaboration%20-%20PPEGC-2025-0002)

---

## Citation

**Recommended citation:**
```
North American Contributor. (2025). BRAF V600E melanoma with PTEN loss and 
primary vemurafenib resistance. Platform for Exceptional Genomic Cancer Cases 
(PPEGC). DOI: 10.ppegc/2025-0002
```

---

## Related Cases

- [PPEGC-2025-0005](#) ‚Äî NRAS-mutant melanoma with MEK inhibitor hypersensitivity
- [PPEGC-2025-0009](#) ‚Äî Triple-negative melanoma with unusual immunotherapy response

---

*Published: February 16, 2025*  
*Last updated: February 16, 2025*

[‚Üê Back to all cases](../cases.html) | [Home](../index.md)
